CTLA4 and ovarian cancer: The increase in local IFNγ in response to the combination of anti-CTLA-4 and PARPis was sufficient to inhibit tumor growth, but this combination had no such effect on BRCA1-sufficient ovarian cancer cells that were inoculated into the mice.